Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Therapy for Stage II/III Cholangiocarcinoma Based on 3D-PTA Susceptibility Testing
NCT07296666Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2025
- Primary completion
- Oct 2027
01
Overview
Phase 2, randomised, open-label trial in cholangiocarcinoma (CCA) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival rate at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07296666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296666.